Inst för onkologi-patologi / Dept of Oncology-Pathology: Recent submissions
Now showing items 1-20 of 365
-
Characterizing cancer cell signaling at the protein level : from targeted to proteome and phosphoproteome‐wide analyses
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-09-11)Proteins are the effectors of cellular functions and the constituting elements of cellular signaling cascades. The ability to analyze the abundances and the dynamics of proteins is central to dissect cellular signaling ... -
Insulin-like growth factor 1 receptor, novel functions and future possibilities
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-09-01)Insulin like growth factor-1 receptor (IGF-1R) has been shown to be important for cancer cell growth and survival, and is often overexpressed in malignant and premalignant tissues. Ligand binding to IGF-1R induces ... -
Validation of biomarkers and digital image analysis in breast pathology
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-08-21)For women worldwide, the risk of developing breast cancer is second only to that of nonmelanoma skin cancer. Significant improvements have been made in survival over the past decades and today about 80 % of the patients ... -
The challenge of co-existence : from graft-versus-host disease to stable mixed chimerism after allogeneic hematopoietic stem cell transplantation
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-08-08)The only curative treatment strategy for many hematologic and inborn immunodeficiency disorders is an allogeneic hematopoietic stem cell transplantation (HSCT). The treatment involves replacing the entire hematopoietic ... -
Beta-arrestins in cancer : linking pro-tumorigenic extracellular activated signaling with the tumor suppressor p53 pathway
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-07-25)The IGF-1R is an important player in cancer development that maintains the malignant phenotype by inducing cell proliferation, survival, transformation, motility and invasiveness. Activation of IGF-R results in its ... -
Tumour microenvironment in serous ovarian cancer
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-05-30)Ovarian cancer is the seventh most common malignancy in women worldwide and the most lethal gynaecological malignancy in developed countries. The epithelial subtype is divided in five main histologic groups, of which the ... -
Studies on microglia in tumor biology and neurobiology
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-05-24)Microglia are innate immune cells that reside in the central nervous system (CNS). Their activities are critical for ensuring the correct microenvironment for brain development and for maintaining homeostasis in the brain ... -
Biological and therapeutic aspects of breast cancer progression
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-05-11)Breast cancer is the second leading cause of cancer related death in women worldwide1. Although majority of primary breast cancers are curable with current treatment strategies, treatment outcome of metastatic breast cancer ... -
Inhibition of 19S proteasome deubiquitinases as a promising strategy in cancer therapy
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-04-28)The ubiquitin proteasome system (UPS) is the main degradation system in the eukaryotic cell and it is involved in the regulation of many crucial cellular pathways; such as signal transduction, proliferation, DNA repair, ... -
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-04-24)Tumor cells overcome anti-tumor responses in part through immunosuppressive mechanisms. There are several immune modulatory mechanisms. Among them, adenosine is an important factor which is generated by both cancer and ... -
Studies of b-AP15 : a novel inhibitor of proteasome deubiquitinase activity
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-04-07)Bortezomib was the first FDA approved proteasome inhibitor that was initially very successful in treatment of multiple myeloma patients but acquired resistance and adverse side-effect highly decreased patients’ quality of ... -
Exploring disease biomarkers and mechanisms using metabolomics
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-03-14)A metabolome is the complete set of small molecules or metabolites present in a biological system. It is the result of internal, genetically determined processes, as well as external factors. The metabolome can consequently ... -
A framework for organ dose estimation in x-ray angiography and interventional radiology based on dose-related data in DICOM structured reports.
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-03-07)Although interventional x-ray angiography (XA) procedures involve relatively high radiation doses that can lead to deterministic tissue reactions in addition to stochastic effects, convenient and accurate ... -
Molecular aspects of tumor development and treatment for small intestinal neuroendocrine tumors
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2017-01-09)Small intestinal neuroendocrine tumors (SI-NETs) may cause symptoms due to excess secretion of hormones and peptides. The molecular mechanisms behind development of SINETs are not well understood. Copy number alterations, ... -
Ductal adenocarcinoma of the prostate : a morphological, immunohistochemical and genetic study
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2016-11-16)Ductal adenocarcinoma of the prostate (DAC) is the second most common prostate cancer subtype. Patients with DAC often present at an advanced clinicopathological stage, with or without metastases. Patients have a high ... -
Activity and mechanism of action of histone deacetylase inhibitors in synovial sarcoma
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2016-10-05)Synovial sarcoma is a rare but aggressive paediatric soft tissue sarcoma that is driven by the genomic rearrangement t(X;18)(p11.2;q11.2). The resulting fusion protein, SS18- SSX, exhibits oncogenic properties through ... -
Stroma and vessel characteristics in cancer : impact on prognosis and response to treatment
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2016-09-26)A series of pre-clinical and clinical studies imply vessel and pericyte status as determinants of tumor growth, metastasis and response to treatment. These studies thus imply biomarkerpotential of these features. Earlier ... -
Unravelling molecular mechanisms underlying therapy resistance in cutaneous melanoma
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2016-09-07)For many years the standard treatment of advanced metastatic melanoma with chemotherapeutic agents, including temozolomide (TMZ) and dacarbazine (DTIC), has been unsuccessful. The paradigm shift in melanoma treatment ... -
Stereotactic body radiation therapy of lung tumours : clinical and dosimetric aspects
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2016-08-29)The general aim of this thesis was to increase the knowledge regarding some clinical and methodological aspects, relevant in view of toxicity as well as tumour control, in stereotactic body radiation therapy (SBRT) of lung ... -
Therapeutic response in human cancers : the dual role of STAT signalling
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2016-08-08)STAT proteins were discovered as the mediators of interferon (IFN) signalling in response to viral infections. Later, it has become evident that STATs are activated by many stimuli and that they exert multifaceted effects ...